163 related articles for article (PubMed ID: 1850423)
1. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator.
Behrendt N; Ploug M; Patthy L; Houen G; Blasi F; Danø K
J Biol Chem; 1991 Apr; 266(12):7842-7. PubMed ID: 1850423
[TBL] [Abstract][Full Text] [Related]
2. N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand.
Møller LB; Pöllänen J; Rønne E; Pedersen N; Blasi F
J Biol Chem; 1993 May; 268(15):11152-9. PubMed ID: 8388383
[TBL] [Abstract][Full Text] [Related]
3. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR.
Fowler B; Mackman N; Parmer RJ; Miles LA
Thromb Haemost; 1998 Jul; 80(1):148-54. PubMed ID: 9684801
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator.
Solberg H; Løber D; Eriksen J; Ploug M; Rønne E; Behrendt N; Danø K; Høyer-Hansen G
Eur J Biochem; 1992 Apr; 205(2):451-8. PubMed ID: 1374026
[TBL] [Abstract][Full Text] [Related]
5. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.
Behrendt N; Rønne E; Ploug M; Petri T; Løber D; Nielsen LS; Schleuning WD; Blasi F; Appella E; Danø K
J Biol Chem; 1990 Apr; 265(11):6453-60. PubMed ID: 2156852
[TBL] [Abstract][Full Text] [Related]
6. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol.
Ploug M; Rønne E; Behrendt N; Jensen AL; Blasi F; Danø K
J Biol Chem; 1991 Jan; 266(3):1926-33. PubMed ID: 1846368
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
Lijnen HR; De Cock F; Collen D
Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens.
Reuning U; Bang NU
Arterioscler Thromb; 1992 Oct; 12(10):1161-70. PubMed ID: 1327097
[TBL] [Abstract][Full Text] [Related]
9. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains.
Behrendt N; Ronne E; Dano K
J Biol Chem; 1996 Sep; 271(37):22885-94. PubMed ID: 8798468
[TBL] [Abstract][Full Text] [Related]
10. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
11. Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins.
Ploug M; Kjalke M; Rønne E; Weidle U; Høyer-Hansen G; Danø K
J Biol Chem; 1993 Aug; 268(23):17539-46. PubMed ID: 8394346
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
Hajjar KA; Hamel NM
J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465
[TBL] [Abstract][Full Text] [Related]
13. Epitope mapping of the anti-urokinase monoclonal antibody 5B4 by isolated domains of urokinase.
Corti A; Sarubbi E; Soffientini A; Nolli ML; Zanni A; Galimberti M; Parenti F; Cassani G
Thromb Haemost; 1989 Nov; 62(3):934-9. PubMed ID: 2480654
[TBL] [Abstract][Full Text] [Related]
14. Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells.
Ploug M; Rahbek-Nielsen H; Nielsen PF; Roepstorff P; Dano K
J Biol Chem; 1998 May; 273(22):13933-43. PubMed ID: 9593742
[TBL] [Abstract][Full Text] [Related]
15. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the cellular binding site for the urokinase-type plasminogen activator.
Estreicher A; Wohlwend A; Belin D; Schleuning WD; Vassalli JD
J Biol Chem; 1989 Jan; 264(2):1180-9. PubMed ID: 2536017
[TBL] [Abstract][Full Text] [Related]
17. Thrombin decreases the urokinase receptor and surface-localized fibrinolysis in cultured endothelial cells.
Li XN; Varma VK; Parks JM; Benza RL; Koons JC; Grammer JR; Grenett H; Tabengwa EM; Booyse FM
Arterioscler Thromb Vasc Biol; 1995 Mar; 15(3):410-9. PubMed ID: 7749851
[TBL] [Abstract][Full Text] [Related]
18. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification.
Nielsen LS; Kellerman GM; Behrendt N; Picone R; Danø K; Blasi F
J Biol Chem; 1988 Feb; 263(5):2358-63. PubMed ID: 2828365
[TBL] [Abstract][Full Text] [Related]
19. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
Barnathan ES; Kuo A; Rosenfeld L; Karikó K; Leski M; Robbiati F; Nolli ML; Henkin J; Cines DB
J Biol Chem; 1990 Feb; 265(5):2865-72. PubMed ID: 2154462
[TBL] [Abstract][Full Text] [Related]
20. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.
Rønne E; Behrendt N; Ellis V; Ploug M; Danø K; Høyer-Hansen G
FEBS Lett; 1991 Aug; 288(1-2):233-6. PubMed ID: 1715292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
